Viking Therapeutics, Inc. (VKTX)

$ 5.38
-0.29 (-5.11%)
Buy
Symbol VKTX
Price $ 5.38
Beta 1.643
Volume Avg. 0.62M
Market Cap 0.421B
Shares () -
52 Week Range 4.951-10.09
1y Target Est -
DCF Unlevered VKTX DCF ->
DCF Levered VKTX LDCF ->
ROE -18.54% Sell
ROA -18.99% Sell
Operating Margin -
Debt / Equity 5.33% Neutral
P/E -
P/B 1.97 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest VKTX news


Dr. Brian Lian
Healthcare
Biotechnology
Nasdaq Capital Market

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.